Starpharma (ASX:SPL)
ASX announcement history & article coverage
Transparent by design.
Announcments by Starpharma (ASX:SPL) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
DEP HER2 Investor Webinar
DEP milestone triggers partner option fee
Starpharma milestone triggers AUD 0.5 million option fee from Radiopharm with potential AUD 91 million licensing deal
Positive DEP HER2-Lu preclinical data support Phase 1 entry
Starpharma's DEP® HER2-Lu shows promising preclinical data, advancing to Phase 1 trial in H2 2026
DEP radiopharmaceutical data supports patent application
Starpharma files patent for DEP® radiopharmaceutical platform after positive preclinical data
Becoming a substantial holder
Becoming a substantial holder
Quarterly Activities/Appendix 4C Cash Flow Report
Starpharma confirms FDA alignment for DEP® HER2 phase 1 trial, advances partnerships, reports $14.1M cash
FDA confirms path to DEP HER2 first-in-human study
FDA endorses Starpharma's DEP® HER2 phase 1 clinical study design, enabling H2 2026 trial start
Becoming a substantial holder